摘要:
The present invention provides thiazolyl-based compounds of formula (I), useful for treating p38 kinase-associated conditions, wherein ring A is phenyl or pyridyl, and X, Y, B, R2, R3, Z1 m and n are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
摘要翻译:本发明提供了可用于治疗p38激酶相关病症的式(I)的噻唑基类化合物,其中环A是苯基或吡啶基,X,Y,B,R 2, Z 3,Z 1和Z 3如本文所定义。 本发明还涉及含有至少一种可用于治疗p38激酶相关病症的本发明化合物的药物组合物,以及抑制哺乳动物中p38激酶活性的方法。
摘要:
The present invention provides thiazolyl-based compounds of formula (I), useful for treating p38 kinase-associated conditions, wherein ring A is phenyl or pyridyl, and X, Y, B, R2, R3, Z1 m and n are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
摘要:
The present invention provides thiazolyl-based compounds of formula (I), useful for treating p38 kinase-associated conditions, wherein ring A is phenyl or pyridyl, and X, Y, B, R2, R3, Z1 m and n are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
摘要翻译:本发明提供了可用于治疗p38激酶相关病症的式(I)的噻唑基类化合物,其中环A是苯基或吡啶基,X,Y,B,R 2, Z 3,Z 1和Z 3如本文所定义。 本发明还涉及含有至少一种可用于治疗p38激酶相关病症的本发明化合物的药物组合物,以及抑制哺乳动物中p38激酶活性的方法。
摘要:
Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R, R1, R2, R5, R6a, R6b, J, K, X and Z are as described in the specification.
摘要:
Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R, R1, R2, R5, R6a, R6b, J, K, X and Z are as described in the specification.
摘要翻译:具有式(I)的化合物及其药学上可接受的盐,前药和溶剂合物可用作激酶抑制剂,其中R 1,R 2,R 2,R 2, R 5,R 6a,R 6b,J,K,X和Z如说明书中所述。
摘要:
Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R, R1, R2, R5, R6a, R6b, J, K, X and Z are as described in the specification.
摘要翻译:具有式(I)的化合物及其药学上可接受的盐,前药和溶剂合物可用作激酶抑制剂,其中R 1,R 2,R 2,R 2, R 5,R 6a,R 6b,J,K,X和Z如说明书中所述。
摘要:
Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R, R1, R2, R5, R6a, R6b, J, K, X and Z are as described in the specification.
摘要翻译:具有式(I)的化合物及其药学上可接受的盐,前药和溶剂合物可用作激酶抑制剂,其中R 1,R 2,R 2,R 2, R 5,R 6a,R 6b,J,K,X和Z如说明书中所述。
摘要:
A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.
摘要:
A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.
摘要:
A compound of Formula I and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula I, and methods of treating conditions associated with the activity of p38 kinase.